Pediatric Psychopharmacology

  • Joseph Biederman
  • Ronald Steingard


The origins of pediatric psychopharmacology can be traced back to 1937, when Bradley published his findings on the use of the stimulant D-amphetamine (Dexedrine®. and others) in agitated children with various diagnoses. Despite its long history, the field of pediatric psychopharmacology has shown relatively little progress over the last 40 years beyond the use of stimulants. Most available information regarding use of psychotropics in the pediatric population has been anecdotal, and very little of it grounded on empirically based studies. Because of the lack of research data, the Food and Drug Administration (FDA) has not recommended the use of most psychotropics in children. This, in turn, has led to the clinical use of limited numbers of psychotropics for few indications and usually at conservative doses.


Anxiety Disorder Tardive Dyskinesia Stimulant Medication Attention Deficit Disorder Hyperactive Child 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Preskorn S. H., Weller E. B., Weller R. A.: Depression in children: Relationship between plasma imipramine levels and response. J Clin Psychiatry 43:450–453, 1982.PubMedGoogle Scholar
  2. 2.
    Biederman J., Baldessarini R., Wright V., et al: Efficacy and safety of desipramine in the treatment of children and adolescents with attention deficit disorder: A double-blind placebo-controlled study. J Am Acad Child Adol Psychiatry 28:777–785, 1989.CrossRefGoogle Scholar
  3. 3.
    Biederman J., Baldessarini R., Wright V., et al: Serum drug levels and cardiovascular findings in children and adolescents with attention deficit disorder treated with high doses of desipramine. J Am Acad Child Adol Psychiatry 28:903–911, 1989.CrossRefGoogle Scholar
  4. 4.
    Zametkin A., Rapoport J. L., Rapoport L. M. D., et al: Treatment of hyperactive children with monoamine oxidase inhibitors: I. Clinical efficacy. Arch Gen Psychiatry 962–966, 1985.Google Scholar
  5. 5.
    Hunt, R. D., Ruud B., Minderaa M. D., et al: The therapeutic effect of clonidine in attention deficit disorder: A comparison with placebo and methylphenidate. Psychopharmacol Bull 22:229–236, 1986.PubMedGoogle Scholar
  6. 6.
    Flament M. F., Rapoport J. L., Berg C. J., Sceery W., Kilts C., Mellstrom B., Linnoila M.: Clomipramine treatment of childhood obsessive compulsive disorder: A double-blind controlled study. Arch Gen Psychiatry 42:977–983, 1985.PubMedCrossRefGoogle Scholar
  7. 7.
    Kraepelin E.: Manic–Depressive Insanity and Paranoia. Edinburgh, E. and S. Livingstone, 1921.Google Scholar
  8. 8.
    Stroeber M., Carlson G.: Predictors of bipolar illness in adolescents with major depression: A follow-up investigation. Adolesc Psychiatry 10:299–319, 1982.Google Scholar

Selected Reading General

  1. 1.
    Biederman J., Jellinek M. S.: Psychopharmacology in children. N Engl JMed 310:968–972, 1984.CrossRefGoogle Scholar
  2. 2.
    Campbell M., Green W., Deutsch S.: Child and Adolescent Psychopharmacology. Beverly Hills, Sage Publications, 1985.Google Scholar
  3. 3.
    Cantwell D. P., Carlson G. A.: Affective Disorders in Childhood and Adolescence—An Update. New York, SP Medical and Scientific Books, 1983.CrossRefGoogle Scholar
  4. 4.
    Carlson G. A.: Classification issues of bipolar disorders in childhood. Psychiatr Dev 2:273–285, 1984.PubMedGoogle Scholar
  5. 5.
    Carlson G. A., Strober M.: Affective disorder in adolescence: Issues in misdiagnosis. J Clin Psychiatry 39:59–66, 1978.PubMedGoogle Scholar
  6. 6.
    Coffey B. J.: Therapeutics III: Pharmacotherapy, in Robson K. (ed): Manual of Clinical Child Psychiatry. Washington, American Psychiatric Press, 1986, pp 149–184.Google Scholar
  7. 7.
    Davis, R. E.: Manic-depressive variant syndrome of childhood: A preliminary report. Am J Psychiatry 136:702–706, 1979.PubMedGoogle Scholar
  8. 8.
    Diagnostic and Statistical Manual of Mental Disorders (DSM-IIIR), ed. 3, revised. Washington, American Psychiatric Press, 1987.Google Scholar
  9. 9.
    Evans R. W., Clay T. H., Gualtieri C. T.: Carbamazepine in pediatric psychiatry. J Am Acad Child Adol Psychiatry 26:2–8, 1987.CrossRefGoogle Scholar
  10. 10.
    Gittelman R. (ed): Anxiety Disorders of Childhood. New York, The Guilford Press, 1986.Google Scholar
  11. 11.
    Gualtieri C. T., Golden R. N., Fahs J. J. : New developments in pediatric psychopharmacology. J Dev Behav Pediatr 4:202–209, 1983.PubMedCrossRefGoogle Scholar
  12. 12.
    Gualtieri C. T., Golden R., Evans R. W., et al: Blood level measurement of psychoactive drugs in pediatric psychiatry. Ther Drug Monit 6:127–141, 1984.PubMedCrossRefGoogle Scholar
  13. 13.
    Gualtieri C. T., Ondrusek M. G., Finley C.: Attention deficit disorders in adults. Clin Neuropharmacol 8:343–356, 1985.PubMedCrossRefGoogle Scholar
  14. 14.
    Hastings J. E., Barkley R. A.: A review of psychophysiological research with hyperkinetic children. J Abnorm Child Psychol 6:413–417, 1978.PubMedCrossRefGoogle Scholar
  15. 15.
    Hechtman L.: Adolescent outcome of hyperactive children treated with stimulants in childhood: A review. Psychopharmacol Bull 21:178–191, 1985.PubMedGoogle Scholar
  16. 16.
    Herskowitz J.: Neurologic presentations of panic disorder in childhood and adolescence. Dev Med Child Neurol 28:617–623, 1986.PubMedCrossRefGoogle Scholar
  17. 17.
    Kuyler P. L., Rosenthal L., Igel G., et al: Psychopathology among children of manic-depressive patients. Biol Psychiatry 15:589–597, 1980.PubMedGoogle Scholar
  18. 18.
    Mannuzza S., Gittleman Klein R., Bonagura N., et al: Hyperactive boys almost grown up: II. Status of subjects without a mental disorder. Arch Gen Psychiatry 45:13–18, 1988.PubMedCrossRefGoogle Scholar
  19. 19.
    Michels R., Cavenar J. O. (eds): Psychiatry, Vol 6: Child Psychiatry (Solnit A. J., Cohen D. J., Schowalter J. E., eds). New York, Basic Books, 1986.Google Scholar
  20. 20.
    Popper C. (ed): Psychiatric Pharmacosciences of Children and Adolescents. Washington, American Psychiatric Press, 1987.Google Scholar
  21. 21.
    Rapoport J. L.: DSM-III-R and pediatric psychopharmacology. Psychopharmacol Bull 21:803–806, 1985.PubMedGoogle Scholar
  22. 22.
    Reiss A. L.: Developmental manifestations in a boy with prepubertal bipolar disorder. J Clin Psychiatry 46:441–443, 1985.PubMedGoogle Scholar
  23. 23.
    Rutter M., Hersov L. (eds): Child and Adolescent Psychiatry: Modern Approaches (ed 2). Boston, Blackwell Scientific Publications, 1985.Google Scholar
  24. 24.
    Rutter M., Tuma H. A., Lann I. S.: Assessment and Diagnosis in Child Psychopathology. New York, The Guilford Press, 1988.Google Scholar
  25. 25.
    Ryan N. D., Puig-Antich J.: Pharmacological treatment of adolescent psychiatric disorders. J Adol Health Care 8:137–142, 1987.CrossRefGoogle Scholar
  26. 26.
    Solnit A. J., Cohen D. J., Schowalter J. E. (eds): Psychiatry, Vol. 6: Child Psychiatry. Philadelphia, J. P. Lippincott, 1986.Google Scholar
  27. 27.
    Sovner R., Hurley A. D.: Do the mentally retarded suffer from affective illness? Arch Gen Psychiatry 40:61–67, 1983.PubMedCrossRefGoogle Scholar
  28. 28.
    Weiss G., Hechtman L.: Hyperactive Children Grown Up. New York, The Guilford Press, 1986.Google Scholar
  29. 29.
    Weller R. A., Weller E. B., Tucker S. G., et al: Mania in prepubertal children: Has it been underdiagnosed? J Affect Disord 11:151–154, 1986.PubMedCrossRefGoogle Scholar
  30. 30.
    Wender P. H.: The Hyperactive Child, Adolescent, and Adult. New York, Oxford University Press, 1987.Google Scholar
  31. 31.
    Werry J. S. (ed): Pediatric Psychopharmacology: The Use of Behavior Modifying Drugs in Childhood. New York, Brunner-Mazel, 1978.Google Scholar
  32. 32.
    White J. H., O’Shanick G.: Juvenile manic–depressive illness. Am J Psychiatry 134:1035–1036, 1977.PubMedGoogle Scholar
  33. 33.
    Wiener J. M.: Psychopharmacology in childhood disorders. Psychiatr Clin North Am 7:831–843, 1984.PubMedGoogle Scholar
  34. 34.
    Zametkin A. J., Rapoport J. L.: Neurobiology of attention deficit disorder with hyperactivity: Where have we come in 50 years? J Am Acad Child Adol Psychiatry 26:676–686, 1987.CrossRefGoogle Scholar

Selected Reading Stimulants

  1. 35.
    Barkley R. A.: The use of psychopharmacology to study reciprocal influences in parent–child interaction. J Abnorm Child Psychol 9:303–310, 1981.PubMedCrossRefGoogle Scholar
  2. 36.
    Barkley R. A., Karlsson J., Pollard S., et al: Developmental changes in the mother–child interactions of hyperactive boys: Effects of two dose levels of Ritalin. J Child Psychol Psychiatry 26:705–715, 1985.PubMedCrossRefGoogle Scholar
  3. 37.
    Bond W. S.: Recognition and treatment of attention deficit disorder. Clin Pharmacol 6:617–624, 1987.Google Scholar
  4. 38.
    Cantwell D. P.: A clinician’s guide to the use of stimulant medication for the psychiatric disorders of children. J Dev Behav Pediatr 1:133–140, 1980.PubMedCrossRefGoogle Scholar
  5. 39.
    Charles L., Schain R.: A four-year follow-up study of the effects of methylphenidate on the behavior and academic achievement of hyperactive children. J Abnorm Child Psychol 9:495–505, 1981.PubMedCrossRefGoogle Scholar
  6. 40.
    Cohen N. J., Thompson L. : Perceptions and attitudes of hyperactive children and their mothers regarding treatment with methylphenidate. Can J Psychiatry 27:40–42, 1982.PubMedGoogle Scholar
  7. 41.
    Comings D. E., Comings B. G.: A controlled study of Tourette syndrome. I. Attention-deficit disorder, learning disorders, and school problems. Am J Hum Genet 41:701–741, 1987.PubMedGoogle Scholar
  8. 42.
    Evans R. W., Gualtieri C. T., Amara I. : Methylphenidate and memory: Dissociated effects in hyperactive children. Psychopharmacology (Berl) 90:211–216, 1986.CrossRefGoogle Scholar
  9. 43.
    Friedmann N., Thomas J., Carr R., et al: Effect on growth in pemoline-treated children with attention deficit disorder. Am J Dis Child 135:329–332, 1981.PubMedGoogle Scholar
  10. 44.
    Gadow K. D.: Effects of stimulant drugs on academic performance in hyperactive and learning disabled children. J Learn Disabil 16:290–299, 1983.PubMedCrossRefGoogle Scholar
  11. 45.
    Gadow K. D.: Prevalence and efficacy of stimulant drug use with mentally retarded children and youth. Psychopharmacol Bull 21:291–303, 1985.PubMedGoogle Scholar
  12. 46.
    Gauthier M.: Stimulant medications in adults with attention deficit disorder. Can J Psychiatry 29:435–440, 1984.PubMedGoogle Scholar
  13. 47.
    Golinko B. E.: Side effects of dextroamphetamine and methylphenidate in hyperactive children—a brief review. Prog Neuropsychopharmacol Biol Psychiatry 8:1–8, 1984.PubMedCrossRefGoogle Scholar
  14. 48.
    Greenhill L. L., Puig-Antich J., Novacenko H., et al: Prolactin, growth hormone and growth responses in boys with attention deficit disorder and hyperactivity treated with methylphenidate. J Am Acad Child Psychiatry 23:58–67, 1984.PubMedCrossRefGoogle Scholar
  15. 49.
    Gualtieri C. T., Wargin W., Kanoy R., et al: Clinical studies of methylphenidate serum levels in children and adults. J Am Acad Child Psychiatry 21:19–26, 1982.PubMedCrossRefGoogle Scholar
  16. 50.
    Hechtman L., Weiss G., Perlman T. : Young adult outcome of hyperactive children who received long-term stimulant treatment. J Am Acad Child Psychiatry 23:261–269, 1984.PubMedCrossRefGoogle Scholar
  17. 51.
    Kalachnik J. E., Sprague R. L., Sleator E. K., et al: Effect of methylphenidate hydrochloride on stature of hyperactive children. Dev Med Child Neurol 24:586–595, 1982.PubMedCrossRefGoogle Scholar
  18. 52.
    Lowe T. L., Cohen D. J., Detlor J., et al: Stimulant medications precipitate Tourette’s syndrome. JAMA 247:1168–1169, 1982.PubMedCrossRefGoogle Scholar
  19. 53.
    Mattes J. A., Gittelman R.: Growth of hyperactive children on maintenance regimen of methylphenidate. Arch Gen Psychiatry 40:317–321, 1983.PubMedCrossRefGoogle Scholar
  20. 54.
    Porrino L. J., Rapoport J. L., Behar D., et al: A naturalistic assessment of the motor activity of hyperactive boys: II. Stimulant drug effects. Arch Gen Psychiatry 40:688–693, 1983.PubMedCrossRefGoogle Scholar
  21. 55.
    Price R. A., Leckman J. F., Pauls D. L., et al: Gilles de la Tourette’s syndrome: Tics and central nervous system stimulants in twins and nontwins. Neurology (NY) 36:232–237, 1986.CrossRefGoogle Scholar
  22. 56.
    Rapoport J. L., Buchsbaum M. S., Zahn T. P., et al: Dextroamphetamine: Cognitive and behavioral effects in normal prepubertal boys. Science 199:560–563, 1978.PubMedCrossRefGoogle Scholar
  23. 57.
    Rapport M. D., DuPaul G. J.: Hyperactivity and methylphenidate: Rate-dependent effects on attention. Int Clin Psychopharmacol 1:45–52, 1986.PubMedCrossRefGoogle Scholar
  24. 58.
    Satterfield J. H., Cantwell D. P., Schell A., et al: Growth of hyperactive children treated with methylphenidate. Arch Gen Psychiatry 36:212–217, 1979.PubMedCrossRefGoogle Scholar
  25. 59.
    Satterfield J. H., Schell A. M., Barb S. D.: Potential risk of prolonged administration of stimulant medication for hyperactive children. J Dev Behav Pediatr 1:102–107, 1980.PubMedCrossRefGoogle Scholar
  26. 60.
    Schmidt K., Solanto M. V., Sanchez-Kappraff M., et al: The effect of stimulant medication on academic performance, in the context of multimodal treatment, in attention deficit disorders with hyperactivity: Two case reports. J Clin Psychopharmacol 4:100–103, 1984.PubMedCrossRefGoogle Scholar
  27. 61.
    Schmidt K.: The effect of stimulant medication in childhood-onset pervasive developmental disorder—a case report. J Dev Behav Pediatr 3:244–246, 1982.PubMedCrossRefGoogle Scholar
  28. 62.
    Shapiro A. K., Shapiro E.: Do stimulants provoke, cause, or exacerbate tics and Tourette’s syndrome? Compr Psychiatry 22:265–273, 1981.PubMedCrossRefGoogle Scholar
  29. 63.
    Steinhausen H. C., Kreuzer E. M.: Learning in hyperactive children: Are there stimulant-related and state-dependent effects? Psychopharmacology (Berl) 74:389–390, 1981.CrossRefGoogle Scholar
  30. 64.
    Swanson J. M., Lerner M., Cantwell D.: Blood levels and tolerance to stimulants in ADDH children. Clin Neuropharmacol 9(Suppl):523–525, 1986.PubMedGoogle Scholar
  31. 65.
    Varley C. K., Trupin E. W.: Double-blind administration of methylphenidate to mentally retarded children with attention deficit disorder: A preliminary study. Am J Ment Defic 86:560–566, 1982.PubMedGoogle Scholar
  32. 66.
    Volkmar F. R., Hoder E. L., Cohen D. J.: Inappropriate uses of stimulant medications. Clin Pediatr (Phila) 24:127–130, 1985.CrossRefGoogle Scholar
  33. 67.
    Wallander J. L., Schroeder S. R., Michelli J. A., et al: Classroom social interactions of attention deficit disorder with hyperactivity children as a function of stimulant medication. J. Pediatr Psychol 12:61–76, 1987.PubMedCrossRefGoogle Scholar
  34. 68.
    Weiss G.: Controversial issues of the pharmacotherapy of the hyperactive child. Can J Psychiatry 26:385–392, 1981.PubMedGoogle Scholar
  35. 69.
    Weizman A., Weitz R., Szekely G. A., et al: Combination of neuroleptic and stimulant treatment in attention deficit disorder with hyperactivity. J Am Acad Child Psychiatry 23:295–298, 1984.PubMedCrossRefGoogle Scholar
  36. 70.
    Wender P. H., Reimherr F. W., Wood D. R.: Stimulant therapy of ’adult hyperactivity’ (letter). Arch Gen Psychiatry 42:840, 1985.PubMedCrossRefGoogle Scholar
  37. 71.
    Zahn T. P., Rapoport J. L., Thompson C. L. : Autonomic and behavioral effects of dextroamphetamine and placebo in normal and hyperactive prepubertal boys. J Abnorm Child Psychol 8:145–160, 1980.PubMedCrossRefGoogle Scholar
  38. 72.
    Zametkin A. J., Karoum F., Linnoila M., et al: Stimulants, urinary catecholamines, and indoleamines in hyperactivity. A comparison of methylphenidate and dextroamphetamine. Arch Gen Psychiatry 42:251–255, 1985.PubMedCrossRefGoogle Scholar


  1. 73.
    Biederman, J., Gastfriend D., Jellinek M. S., et al: Cardiovascular effects of desipramine in children and adolescents with attention deficit disorder. J Pediatr 106:1017–1020, 1985.PubMedCrossRefGoogle Scholar
  2. 74.
    Biederman J., Gastfriend D. R., Jellinek M. S.: Desipramine in treating children with attention deficit disorder. J Clin Psychopharmacol 6:359–363, 1986.PubMedGoogle Scholar
  3. 75.
    Biederman J., Gonzalez E., Bronstein B., et al: Despiramine and cutaneous reactions in pediatric outpatients. J Clin Psychiatry 49:178–183, 1988.PubMedGoogle Scholar
  4. 76.
    Dillon D. C., Salzman I. J., Schulsinger D. A.: The use of imipramine in Tourette’s syndrome and attention deficit disorder: Case report. J Clin Psychiatry 46:348–349, 1985.PubMedGoogle Scholar
  5. 77.
    Donnelly M., Zametkin A. J., Rapoport J. L., et al: Treatment of childhood hyperactivity with desipramine: Plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. Clin Pharmacol Ther 39:72–81, 1986.PubMedCrossRefGoogle Scholar
  6. 78.
    Gastfriend D. R., Biederman J., Jellinek M. S.: Desipramine in treating adolescents with attention deficit disorder. Am J Psychiatry 141:906–908, 1984.PubMedGoogle Scholar
  7. 79.
    Gittelman-Klein R., Klein D.: Controlled imipramine of school phobia. Arch Gen Psychiatry 25:204–207, 1971.CrossRefGoogle Scholar
  8. 80.
    Greenberg L. M., Yellin A. M.: Blood pressure and pulse changes in hyperactive children with imipramine and methylphenidate. Am J Psychiatry 132:1325–1326, 1975.PubMedGoogle Scholar
  9. 81.
    Hoge S. K., Biederman J.: A case of Tourette’s syndrome with symptoms of attention deficit disorder treated with desipramine. J Clin Psychiatry 47:478–479, 1986.PubMedGoogle Scholar
  10. 82.
    Hoge S. K., Biederman J.: Liver function tests during treatment with desipramine in children and adolescents. J Clin Psychopharmacol 7:87–89, 1987.PubMedCrossRefGoogle Scholar
  11. 83.
    Lake C. R., Mikkelsen E. J., Rapoport J. L., et al: Effect of imipramine on norepinephrine and blood pressure in enuretic boys. Clin Pharmacol Ther 26:647–653, 1979.PubMedGoogle Scholar
  12. 84.
    Mikkelsen E. J., Rapoport J. L.: Enuresis: Psychopathology, sleep stage, and drug response. Urol Clin North Am 7:361–377, 1980.PubMedGoogle Scholar
  13. 85.
    Muller U. R., Goodman N., Bellet S.: The hypotensive effect imipramine hydrochloride in patients with cardiovascular disease. Clin Pharmacol Ther 2:300–307, 1961.PubMedGoogle Scholar
  14. 86.
    Rapoport J. L.: Antidepressants in childhood attention deficit disorder and obsessive compulsive disorder. Psychosomatics 27(Suppl):30–36, 1986.PubMedGoogle Scholar
  15. 87.
    Rapoport J. L., Mikkelsen E. J., Zavadil A. P.: Plasma imipramine and desmethylimipramine concentration and clinical response in childhood enuresis. Psychopharmacol Bull 14:60–61, 1978.PubMedGoogle Scholar
  16. 88.
    Rapoport J. L., Mikkelsen E. J., Zavadil A., et al: Childhood enuresis. II. Psychopathology tricyclic concentration in plasma, and antienuretic effect. Arch Gen Psychiatry 37:1146–1152, 1980.PubMedCrossRefGoogle Scholar
  17. 89.
    Ryan N. D., Puig-Antich J., Cooper T., et al: Imipramine in adolescent major depression: Plasma level and clinical response. Acta Psychiatr Scand 73:275–288, 1986.PubMedCrossRefGoogle Scholar
  18. 90.
    Ryan N. D., Puig-Antich J., Cooper T., et al: Relative safety of single versus divided dose imipramine in adolescent major depression. J Am Acad Child Adol Psychiatry 26:400–406, 1987.CrossRefGoogle Scholar
  19. 91.
    Saraf K. R., Klein D. F., Gittelman-Klein R., et al: Imipramine side effects in children. Psychopharmacologia (Berlin) 37:265–274, 1974.CrossRefGoogle Scholar
  20. 92.
    Saraf K. R., Klein D. F., Gittelman-Klein R., et al: EKG effects of imipramine treatment in children. J Am Acad Child Psychiatry 17:60–69, 1978.PubMedCrossRefGoogle Scholar
  21. 93.
    Weller E. B., Weller R. A., Preskorn S. H., et al: Steady-state plasma imipramine levels in prepubertal children. Am J Psychiatry 139:506–508, 1982.PubMedGoogle Scholar
  22. 94.
    Zametkin A., Rapoport J. L., Murphy D. L., et al: Treatment of hyperactive children with monoamine oxidase inhibitors. I. Clinical efficacy. Arch Gen Psychiatry 42:962–966, 1985.PubMedCrossRefGoogle Scholar
  23. 95.
    Zametkin A., Rapoport J. L., Murphy D. L., et al: Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment. Arch Gen Psychiatry 42:969–973, 1985.PubMedCrossRefGoogle Scholar


  1. 96.
    Campbell M., Schulman D., Rapoport J. L.: The current status of lithium therapy in child and adolescent psychiatry. A report of the Committee on Biological Aspects of Child Psychiatry of the American Academy of Child Psychiatry, December 1977. J Am Acad Child Psychiatry 17:717–720, 1978.PubMedCrossRefGoogle Scholar
  2. 97.
    Campbell M., Small A. M., Green W. H., et al: Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 41:650–656, 1984.PubMedCrossRefGoogle Scholar
  3. 98.
    Carroll J. A., Jefferson J. W., Greist J. H.: Psychiatric uses of lithium for children and adolescents. Hosp Community Psychiatry 38:927–928, 1987.PubMedGoogle Scholar
  4. 99.
    DeLong G. R., Aldersh A. L.: Long-term experience with lithium treatment in childhood: Correlation with clinical diagnosis. J Am Acad Child Adol Psychiatry 26:389–394, 1987.CrossRefGoogle Scholar
  5. 100.
    Hsu L. K.: Lithium-resistant adolescent mania. J Am Acad Child Psychiatry 25:280–283, 1986.PubMedCrossRefGoogle Scholar
  6. 101.
    Jefferson J. W.: The use of lithium in childhood and adolescence: An overview. J Clin Psychiatry 43:174–177, 1982.PubMedGoogle Scholar
  7. 102.
    Khandelwal S. K., Varma V. K., Srinivasa-Murthy R.: Renal function in children receiving longterm lithium prophylaxis. Am J Psychiatry 141:278–279, 1984.PubMedGoogle Scholar
  8. 103.
    Lena B.: Lithium in child and adolescent psychiatry. Arch Gen Psychiatry 36(Spec No):854–855, 1979.PubMedCrossRefGoogle Scholar
  9. 104.
    Marini J. L., Sheard M. H.: Antiaggressive effect of lithium ion in man. Acta Psychiatr Scand 55:269–286, 1977.PubMedCrossRefGoogle Scholar
  10. 105.
    McKnew D. H., Cytryn L., Buchsbaum M. S., et al: Lithium in children of lithium-responding parents. Psychiatry Res 4:171–180, 1981.PubMedCrossRefGoogle Scholar
  11. 106.
    Perry R., Campbell M., Grega D. M., et al: Saliva lithium levels in children: Their use in monitoring serum lithium levels and lithium side effects. J Clin Psychopharmacol 4:199–202, 1984.PubMedGoogle Scholar
  12. 107.
    Platt J. E., Campbell M., Green W. H., et al: Cognitive effects of lithium carbonate and haloperidol in treatment-resistant aggressive children. Arch Gen Psychiatry 41:657–662, 1984.PubMedCrossRefGoogle Scholar
  13. 108.
    Platt J. E., Campbell M., Green W. H., et al: Effects of lithium carbonate and haloperidol on cognition in aggressive hospitalized school-age children. J Clin Psychopharmacol 1:8–13, 1981.PubMedCrossRefGoogle Scholar
  14. 109.
    Rogeness G. A., Riester A. E., Wicf J. S.: Unusual presentation of manic depressive disorder in adolescence. J Clin Psychiatry 43:37–39, 1982.PubMedGoogle Scholar
  15. 110.
    Siassi I.: Lithium treatment of impulsive behavior in children. J Clin Psychiatry 43:482–484, 1982.PubMedGoogle Scholar
  16. 111.
    Steinberg D.: The use of lithium carbonate in adolescence. J Child Psychol Psychiatry 21:263–271, 1980.PubMedCrossRefGoogle Scholar
  17. 112.
    Steingard R., Biederman J.: Lithium responsive manic-like symptoms in two individuals with autism and mental retardation. Am Acad Child Adol Psychiatry 26:932–935, 1987.CrossRefGoogle Scholar
  18. 113.
    Thorneloe W. F., Crews E. L.: Manic depressive illness concomitant with antisocial personality disorder: Six case reports and review of the literature. J Clin Psychiatry 42:5–9, 1981.PubMedGoogle Scholar
  19. 114.
    Vetro A., Szentistvanyi I., Pallag L., et al: Therapeutic experience with lithium in childhood aggressivity. Neuropsychobiology 14:121–127, 1985.PubMedCrossRefGoogle Scholar
  20. 115.
    Vitiello B., Behar D., Ryan P., et al: Saliva lithium monitoring [letter]. J Am Acad Child Adol Psychiatry 26:812–813, 1987.CrossRefGoogle Scholar
  21. 116.
    Weller E. B., Weller R. A., Fristad M. A., et al: Saliva lithium monitoring in prepubertal children. J Am Acad Child Adol Psychiatry 26:173–175, 1987.CrossRefGoogle Scholar
  22. 117.
    Weller E. B., Weller R. A., Fristad M. A.: Lithium dosage guide for prepubertal children: A preliminary report. J Am Acad Child Psychiatry 25:92–95, 1986.PubMedCrossRefGoogle Scholar
  23. 118.
    Youngerman J., Canino I. A.: Lithium carbonate use in children and adolescents. A survey of the literature. Arch Gen Psychiatry 35:216–224, 1978.PubMedCrossRefGoogle Scholar
  24. AntipsychoticsGoogle Scholar
  25. 119.
    Biederman J., Lerner Y., Belmaker R. H.: Combination of lithium carbonate and haloperidol in schizo-affective disorder: A controlled study. Arch Gen Psychiatry 36:327–333, 1979.PubMedCrossRefGoogle Scholar
  26. 120.
    Campbell M., Fish B., Shapiro T., et al: Acute responses of schizophrenic children to a sedative and a“stimulating” neuroleptic: A pharmacologic yardstick. Curr Ther Res 14:759–766, 1972.PubMedGoogle Scholar
  27. 121.
    Campbell M., Grega D. M., Green W. H., et al.: Neuroleptic-induced dyskinesias in children. Clin Neuropharmacol 6:207–222, 1983.PubMedCrossRefGoogle Scholar
  28. 122.
    Gualtieri C. T., Patterson D. R.: Neuroleptic-induced tics in two hyperactive children. Am J Psychiatry 143:1176–1177, 1983.Google Scholar
  29. 123.
    Gualtieri C. T., Guimond M.: Tardive dyskinesia and the behavioral consequences of chronic neuroleptic treatment. Dev Med Child Neurol 23:255–259, 1981.PubMedCrossRefGoogle Scholar
  30. 124.
    Gualtieri C. T., Hawk B.: Tardive dyskinesia and other drug-induced movement disorders among handicapped children and youth. Appl Res Ment Retard 1:55–69, 1980.PubMedCrossRefGoogle Scholar
  31. 125.
    Gualtier C. T., Quade D., Hicks R. E., et al: Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Am J Psychiatry 141:20–23, 1984.Google Scholar
  32. 126.
    Gualtieri C. T., Sprague R. L.: Preventing tardive dyskinesia and preventing tardive dyskinesia litigation. Psychopharmacol Bull 20:346–348, 1984.PubMedGoogle Scholar
  33. 127.
    Perry R., Campbell M., Green W. H., et al: Neuroleptic-related dyskinesias in autistic children: A prospective study. Psychopharmacol Bull 21:140–143, 1985.PubMedGoogle Scholar

Antianxiety Agents

  1. 128.
    Biederman J.: Clonazepam in treating prepubertal children with panic-like symptoms. J Clin Psychiatry 48(Suppl):38–42, 1987.PubMedGoogle Scholar
  2. 129.
    Emde R. N.: Early development and opportunities for research on anxiety, in Tuma A. H., Maser J. D. (eds): Anxiety and the Anxiety Disorders. Hillsdale, NJ, Lawrence Erlbaum, 1986, pp 413–420.Google Scholar
  3. 130.
    Gittelman R., Koplewicz H. S.: Pharmacotherapy of childhood anxiety disorders, in Gittelman R. (ed): Anxiety Disorders in Children. New York, Guilford Press, 1987, pp 188–203.Google Scholar
  4. 131.
    Simeon J. G., Ferguson H. B.: Alprazolam effects in children with anxiety disorders. Can J Psychiatry 32:570–574, 1987.PubMedGoogle Scholar


  1. 132.
    August G. J., Naftali R., Papanicolaou A. C., et al: Fenfluramine treatment in infantile autism: Neurochemical, electrophysiological, and behavioral effects. J Nerv Ment Dis 172:604–612, 1984.PubMedCrossRefGoogle Scholar
  2. 133.
    Campbell M., Small A. M., Palij M., et al: Efficacy and safety of fenfluramine in autistic children: Preliminary analysis of a double-blind study. Psychopharmacol Bull 23:123–128, 1987.PubMedGoogle Scholar
  3. 134.
    Donnelly M., Rapoport J. L., Ismond D. R.: Fenfluramine treatment of childhood attention deficit disorder with hyperactivity: A preliminary report. Psychopharmacol Bull 22:152–154, 1986.PubMedGoogle Scholar
  4. 135.
    Geller E., Ritvo E. R., Freeman B. J., et al: Fenfluramine in autism. N Engl J Med 307:1450–1451, 1982.CrossRefGoogle Scholar
  5. 136.
    Geller E., Ritvo E. R., Freeman B. J., et al: Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med 307:165–168, 1982.PubMedCrossRefGoogle Scholar
  6. 137.
    Ritvo E. R., Freeman B. J., Geller E., et al: Effects of fenfluramine on 14 outpatients with the syndrome autism. J Am Acad Child Psychiatry 22:549–558, 1983.CrossRefGoogle Scholar
  7. 138.
    Ritvo E. R., Freeman B. J., Yuwiler A., et al: Study of fenfluramine in outpatients with the syndrome autism. J Pediatr 105:823–828, 1984.PubMedCrossRefGoogle Scholar
  8. 139.
    Volkmar F. R., Paul R., Cohen D. J., et al: Irritability in autistic children treated with fenfluramine (letter). N Engl J Med 309:187, 1983.PubMedGoogle Scholar


  1. 140.
    Cohen D. J., Detlor J., Young J. G., et al: Clonidine ameliorates of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 37:1350–1357, 1980.PubMedCrossRefGoogle Scholar
  2. 141.
    Goetz C. G., Tanner C. M., Wilson R. S., et al: Clonidine and Gilles de la Tourette’s syndrome: Double-blind study using objective rating methods. Ann Neurol 21:307–310, 1987.PubMedCrossRefGoogle Scholar
  3. 142.
    Hunt R. D.: Treatment effects of oral and transdermal clonidine in relation to methylphenidate: An open pilot study in ADD-H. Psychopharmacol Bull 1:111–114, 1987.Google Scholar
  4. 143.
    Hunt R. D., Ruud B., Minderaa M. D., et al: Clonidine benefits children with attention deficit disorder and hyperactivity: Report of a double-blind placebo—crossover therapeutic trial. J Am Acad Child Psychiatry 5:617–629, 1985.Google Scholar
  5. 144.
    Hunt R. D., Ruud B., Minderaa M. D., et al: The therapeutic effect of clonidine in attention deficit disorder: A comparison with placebo and methylphenidate. Psychopharmacol Bull 1:229–236, 1986.Google Scholar
  6. 145.
    Leckman J. F., Detlor J., Harcherik D. F., et al: Short- and long-term treatment of Tourette’s syndrome with clonidine: A clinical perspective. Neurology 35:343–351, 1985.PubMedCrossRefGoogle Scholar

β Blockers

  1. 146.
    Dominguez R. A., Goldstein B. J.: Beta-blockers in psychiatry. Hosp Comm Psychiatry 6:565–566, 568, 1984.Google Scholar
  2. 147.
    Jenkins S. C., Maruta T.: Therapeutic use of propanolol for intermittent explosive disorder. Mayo Clin Proc 62:204–214, 1987.PubMedCrossRefGoogle Scholar
  3. 148.
    Lipinski J. F., Zubenko G. S., Cohen B. M., et al: Propranolol in treating neuroleptic-induced akathisia. Am J Psychiatry 3:412–415, 1984.Google Scholar
  4. 149.
    Ratey J. J., Mikkelsen E. J., Smith G. B., et al: Beta-blockers in the severely and profoundly mentally retarded. J Clin Psychopharmacol 2:103–107, 1984.Google Scholar
  5. 150.
    Sorgi P. J., Ratey J. J., Polakf S.: Beta-adrenergic blockers for the control of aggressive behaviors in patients with chronic schizophrenia. Am J Psychiatry 6:775–776, 1986.Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Joseph Biederman
    • 1
    • 2
  • Ronald Steingard
    • 1
    • 2
  1. 1.Department of PsychiatryHarvard Medical SchoolBostonUSA
  2. 2.Pediatric Psychopharmacology UnitMassachusetts General HospitalBostonUSA

Personalised recommendations